Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
These re-agent and diagnostic test kits come with 99.7% accuracy
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Subscribe To Our Newsletter & Stay Updated
